Artivion (NYSE:AORT) Reaches New 1-Year High – Time to Buy?

Artivion, Inc. (NYSE:AORT)’s share price reached a new 52-week high during mid-day trading on Wednesday . The stock traded as high as $30.10 and last traded at $29.94, with a volume of 36052 shares. The stock had previously closed at $29.68.

Wall Street Analyst Weigh In

A number of equities analysts recently commented on the stock. JMP Securities started coverage on shares of Artivion in a report on Wednesday, October 23rd. They set an “outperform” rating and a $33.00 price target on the stock. Stifel Nicolaus boosted their target price on Artivion from $28.00 to $30.00 and gave the company a “buy” rating in a research report on Friday, September 13th. Needham & Company LLC reiterated a “buy” rating and issued a $30.00 price target on shares of Artivion in a report on Friday, September 27th. Finally, Oppenheimer boosted their price objective on Artivion from $30.00 to $32.00 and gave the company an “outperform” rating in a report on Friday, November 8th. Five research analysts have rated the stock with a buy rating, According to MarketBeat.com, the company has an average rating of “Buy” and a consensus price target of $31.00.

Artivion Trading Down 0.2 %

The stock’s 50-day moving average price is $27.17 and its 200 day moving average price is $25.91. The company has a debt-to-equity ratio of 0.71, a current ratio of 1.88 and a quick ratio of 1.33. The firm has a market capitalization of $1.24 billion, a PE ratio of -1,484.00 and a beta of 1.75.

Insiders Place Their Bets

In related news, CAO Amy Horton sold 12,430 shares of the company’s stock in a transaction dated Tuesday, October 1st. The shares were sold at an average price of $26.18, for a total value of $325,417.40. Following the completion of the sale, the chief accounting officer now directly owns 139,989 shares of the company’s stock, valued at $3,664,912.02. This represents a 8.16 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 8.10% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in the business. Vanguard Group Inc. boosted its stake in shares of Artivion by 1.3% during the first quarter. Vanguard Group Inc. now owns 2,664,855 shares of the company’s stock valued at $56,388,000 after purchasing an additional 33,982 shares in the last quarter. Price T Rowe Associates Inc. MD boosted its position in Artivion by 5.1% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 33,690 shares of the company’s stock valued at $713,000 after acquiring an additional 1,634 shares in the last quarter. Tidal Investments LLC purchased a new position in shares of Artivion in the 1st quarter valued at $257,000. Louisiana State Employees Retirement System raised its position in shares of Artivion by 3.1% in the 2nd quarter. Louisiana State Employees Retirement System now owns 19,900 shares of the company’s stock worth $510,000 after acquiring an additional 600 shares in the last quarter. Finally, Bank of New York Mellon Corp lifted its stake in shares of Artivion by 0.7% during the 2nd quarter. Bank of New York Mellon Corp now owns 301,992 shares of the company’s stock worth $7,746,000 after purchasing an additional 2,018 shares during the last quarter. Hedge funds and other institutional investors own 86.37% of the company’s stock.

About Artivion

Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.